An incubator supporting UK SMEs in the transformation of chemistry into the digital domain.
Learn more about the iDMT
The mission of the Innovation Centre in Digital Molecular Technologies (iDMT) is to support UK SMEs in:
(i) Establishing new products and services to support the digital transformation of the molecular industries, and
(ii) Exploiting the power of AI and machine learning in molecular sciences, technologies and products.
The iDMT is an open innovation research centre, co-funded by the University of Cambridge, AstraZeneca, Shionogi and European Regional Development Fund (ERDF). Find out more about our partners >
We work with SMEs to help them develop new products and services to serve the emerging digital chemistry market. The iDMT undertakes collaborative research projects in three key ditigal molecular technology areas:
Artificial intelligence in molecular technologies
Robotic equipment for chemical synthesis
Algorithms for digital process development
Our business support will include access to lab space and a collaborative research environment; participation in joint development with leading researchers from academia and the pharmaceutical industry; and access to equipment, materials and computational resources.
University of Cambridge
The University is one of the world’s oldest universities and leading academic centres, and a self-governed community of scholars. The University is a home of 20,000 students from all walks of life and all corners of the world, over 11,000 staff, 31 Colleges and 150 Departments, Faculties, Schools and other institutions.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve”. We recently announced our 2030 vision “Building Innovation Platforms to Shape the Future of Healthcare” and the medium-term business plan “STS2030” for the realization of the vision.
The iDMT team is composed of:
World leading experts from the University of Cambridge in fields including sustainable engineering, probabilistic machine learning and chemical synthesis.
Insights from industrial partners from global pharmaceutical companies.